Skip to Content

  • Search

View Additional Section Content

Incyte INCB 24360-210: A Randomized, Open Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects with Biochemical-Recurrent Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma or Fallopian TubeCancer Following Complete Remission with First-Line Chemotherapy

Clinical Trial Categories

  • Ovarian Cancer
Hanjani Institute for Gynecologic Oncology at 215-885-0220


  • Hanjani Institute for Gynecologic Oncology
    The Rosenfeld Cancer Center
    1200 Old York Rd, AMH - 1 Widener
    Abington, PA 19001
    Office: 215-885-0220
    Fax: 215-576-0740

Find a Physician
Search Our Directory


Schedule a Test
Request an Appointment


Clinical Trials Details